CYP19A1 and breast carcinoma: Targeting ER function in luminal breast cancers with selective ER modulators (SERMs, such as tamoxifen) and/or aromatase inhibitors (for example, anastrozole, letrozole, or exemestane) is very effective for a majority of women [87,88].